Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

[MSI Metastatic solid tumors treatment and immunotherapies].

Bouchez C, Kempf E, Tournigand C.

Bull Cancer. 2019 Feb;106(2):143-150. doi: 10.1016/j.bulcan.2019.01.008. Epub 2019 Feb 5. Review. French.

PMID:
30737018
2.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A.

Int J Oncol. 2019 Feb 1. doi: 10.3892/ijo.2019.4709. [Epub ahead of print]

PMID:
30720091
3.

[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].

Cohen R, Heran M, Pudlarz T, Hilmi M, Tournigand C, André T, Rousseau B.

Bull Cancer. 2019 Feb;106(2):151-161. doi: 10.1016/j.bulcan.2018.09.008. Epub 2019 Jan 11. Review. French.

PMID:
30638897
4.

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).

Watson S, Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C.

Eur J Cancer. 2019 Jan;107:46-52. doi: 10.1016/j.ejca.2018.11.006. Epub 2018 Dec 7.

PMID:
30529902
5.

Preferences for surrogate designation and decision-making process in older versus younger adults with cancer: A comparative cross-sectional study.

Martinez-Tapia C, Canoui-Poitrine F, Caillet P, Bastuji-Garin S, Tournigand C, Assaf E, Varnier G, Pamoukdjian F, Brain E, Rollot-Trad F, Laurent M, Paillaud E; ELCAPA Study Group.

Patient Educ Couns. 2018 Sep 29. pii: S0738-3991(18)30814-0. doi: 10.1016/j.pec.2018.09.024. [Epub ahead of print]

PMID:
30293935
6.

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma.

Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, Azoulay D, Salloum C, Laurent A, de la Taille A, Salomon L, Cholley I, Haioun C, Dupuis J, Wolkenstein P, Matignon MB, Grimbert P, Tournigand C.

Int J Cancer. 2019 Feb 15;144(4):886-896. doi: 10.1002/ijc.31769. Epub 2018 Nov 20.

PMID:
30155929
7.

Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.

Lim C, Doussot A, Osseis M, Esposito F, Salloum C, Calderaro J, Tournigand C, Azoulay D.

Clin Transl Oncol. 2018 Oct;20(10):1274-1279. doi: 10.1007/s12094-018-1858-8. Epub 2018 Mar 28.

PMID:
29594943
8.

Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death.

Król A, Tournigand C, Michiels S, Rondeau V.

Stat Med. 2018 Jun 15;37(13):2148-2161. doi: 10.1002/sim.7640. Epub 2018 Mar 26.

PMID:
29579780
9.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

10.

Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.

Mésange P, Bouygues A, Ferrand N, Sabbah M, Escargueil AE, Savina A, Chibaudel B, Tournigand C, André T, de Gramont A, Larsen AK.

Clin Cancer Res. 2018 Jun 1;24(11):2548-2558. doi: 10.1158/1078-0432.CCR-17-3187. Epub 2018 Feb 28.

PMID:
29490990
11.

Hospital end-of-life care in haematological malignancies.

Beaussant Y, Daguindau E, Chauchet A, Rochigneux P, Tournigand C, Aubry R, Morin L.

BMJ Support Palliat Care. 2018 Sep;8(3):314-324. doi: 10.1136/bmjspcare-2017-001446. Epub 2018 Feb 6.

PMID:
29434048
12.

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.

Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, André T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S.

Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031.

13.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

14.

Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.

Laroche F, Perrot S, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Chauvenet L, Bouhassira D, Coste J.

PLoS One. 2017 Nov 8;12(11):e0187165. doi: 10.1371/journal.pone.0187165. eCollection 2017.

15.

Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer.

Martinez-Tapia C, Paillaud E, Liuu E, Tournigand C, Ibrahim R, Fossey-Diaz V, Culine S, Canoui-Poitrine F, Audureau E; ELCAPA Study Group.

Eur J Cancer. 2017 Sep;83:211-219. doi: 10.1016/j.ejca.2017.06.027. Epub 2017 Jul 24.

PMID:
28750273
16.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.

Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C.

Pharmacol Ther. 2018 Jan;181:49-75. doi: 10.1016/j.pharmthera.2017.07.006. Epub 2017 Jul 16. Review.

PMID:
28723416
17.

Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.

Allard M, Khoudour N, Rousseau B, Joly C, Costentin C, Blanchet B, Tournigand C, Hulin A.

J Pharm Biomed Anal. 2017 Aug 5;142:42-48. doi: 10.1016/j.jpba.2017.04.053. Epub 2017 May 1.

PMID:
28494338
18.
19.

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.

Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J.

Oncotarget. 2017 Apr 11;8(15):24644-24651. doi: 10.18632/oncotarget.15602.

20.

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A.

Ann Oncol. 2017 Sep 1;28(9):2077-2085. doi: 10.1093/annonc/mdx191. Review.

PMID:
28430862
21.

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.

Bourdais R, Rousseau B, Pujals A, Boussion H, Joly C, Guillemin A, Baumgaertner I, Neuzillet C, Tournigand C.

Crit Rev Oncol Hematol. 2017 May;113:242-248. doi: 10.1016/j.critrevonc.2017.03.027. Epub 2017 Mar 23. Review.

PMID:
28427513
22.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

23.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.

PMID:
28397697
24.

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx037.

PMID:
28383673
25.

[De novo cancer after solid organ transplantation: Epidemiology, prognosis and management].

Guillemin A, Rousseau B, Neuzillet C, Joly C, Boussion H, Grimbert P, Compagnon P, Duvoux C, Tournigand C.

Bull Cancer. 2017 Mar;104(3):245-257. doi: 10.1016/j.bulcan.2016.12.008. Epub 2017 Feb 23. Review. French.

PMID:
28237352
26.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.

Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C.

Pharmacol Ther. 2017 Jun;174:145-172. doi: 10.1016/j.pharmthera.2017.02.028. Epub 2017 Feb 14. Review.

PMID:
28223233
27.

Supportive Care Organization in France: a national in-depth survey among patients and oncologists.

Scotté F, Hervé C, Leroy P, Tourani JM, Bensadoun RJ, Bugat ME, Farsi F, Jovenin N, Namer M, Tournigand C, Morin S, Brami C, Oudard S, Saadi A, Krakowski I.

Support Care Cancer. 2017 Jul;25(7):2111-2118. doi: 10.1007/s00520-017-3615-x. Epub 2017 Feb 20.

PMID:
28220314
28.

Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study.

Ferrat E, Paillaud E, Caillet P, Laurent M, Tournigand C, Lagrange JL, Droz JP, Balducci L, Audureau E, Canouï-Poitrine F, Bastuji-Garin S.

J Clin Oncol. 2017 Mar;35(7):766-777. doi: 10.1200/JCO.2016.69.3143. Epub 2017 Jan 17.

29.

Use of chemotherapy near the end of life: what factors matter?

Rochigneux P, Raoul JL, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, Morin L.

Ann Oncol. 2017 Apr 1;28(4):809-817. doi: 10.1093/annonc/mdw654.

PMID:
27993817
30.

First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.

Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, Boussion H, Neuzillet C, Macquin-Mavier I, Oudard S, Salomon L, de la Taille A, Tournigand C.

Crit Rev Oncol Hematol. 2016 Nov;107:44-53. doi: 10.1016/j.critrevonc.2016.08.012. Epub 2016 Sep 1. Review.

PMID:
27823651
31.

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Boissier E, Mir O, Hollebecque A, Izzedine H, Ederhy S, Gazzah A, Bahleda R, Massard C, Macquin-Mavier I, Tournigand C, Spano JP, Soria JC, Rousseau B.

Invest New Drugs. 2017 Feb;35(1):79-86. doi: 10.1007/s10637-016-0402-3. Epub 2016 Oct 25.

PMID:
27783256
32.

[Are cancer outpatients ready for e-medicine?]

Kempf E, Prévost A, Rousseau B, Macquin-Mavier I, Louvet C, Tournigand C.

Bull Cancer. 2016 Oct;103(10):841-848. doi: 10.1016/j.bulcan.2016.06.004. Epub 2016 Aug 3. French.

PMID:
27497498
33.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group.

Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12.

34.

Laparoscopic vs. open surgery for T4 colon cancer: A propensity score analysis.

de'Angelis N, Vitali GC, Brunetti F, Wassmer CH, Gagniere C, Puppa G, Tournigand C, Ris F.

Int J Colorectal Dis. 2016 Nov;31(11):1785-1797. Epub 2016 Sep 14.

PMID:
27627964
35.

What Do Older Adults Know About Their Cancer Diagnosis and Treatment? The ELCAPA-08 Cohort Study.

Kempf E, Caillet P, Rousseau B, Le Thuaut A, Bastuji-Garin S, Liuu E, Lagrange JL, Tournigand C, Paillaud E, Canouï-Poitrine F.

J Am Geriatr Soc. 2016 Jun;64(6):1360-2. doi: 10.1111/jgs.14154. No abstract available.

PMID:
27321623
36.

End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study.

Gallais Sérézal I, Beaussant Y, Rochigneux P, Tournigand C, Aubry R, Lindelöf B, Morin L.

Br J Dermatol. 2016 Sep;175(3):583-92. doi: 10.1111/bjd.14631. Epub 2016 Aug 9.

PMID:
27038100
37.

Four Distinct Health Profiles in Older Patients With Cancer: Latent Class Analysis of the Prospective ELCAPA Cohort.

Ferrat E, Audureau E, Paillaud E, Liuu E, Tournigand C, Lagrange JL, Canoui-Poitrine F, Caillet P, Bastuji-Garin S; ELCAPA Study Group.

J Gerontol A Biol Sci Med Sci. 2016 Dec;71(12):1653-1660. Epub 2016 Mar 22.

38.

[Medical management of cholangiocarcinomas in 2015].

Marret G, Neuzillet C, Rousseau B, Tournigand C.

Bull Cancer. 2016 Apr;103(4):389-99. doi: 10.1016/j.bulcan.2016.01.019. Epub 2016 Feb 24. Review. French.

PMID:
26922666
39.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.

Cancer Med. 2016 Apr;5(4):676-83. doi: 10.1002/cam4.635. Epub 2016 Jan 24.

40.

Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version.

Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, Soubeyran P, Mathoulin-Pelissier S, Tournigand C, Paillaud E, Laurent M, Audureau E; ELCAPA Study Group.

Oncologist. 2016 Feb;21(2):188-95. doi: 10.1634/theoncologist.2015-0326. Epub 2016 Jan 13.

41.

Maintenance treatment in metastatic colorectal cancer.

Chibaudel B, Bonnetain F, Tournigand C, de Gramont A.

Lancet Oncol. 2015 Dec;16(16):e583-4. doi: 10.1016/S1470-2045(15)00448-9. No abstract available.

PMID:
26678202
42.

Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review.

Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A.

Ther Adv Med Oncol. 2015 May;7(3):153-69. doi: 10.1177/1758834015572343. Review.

43.

Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.

Laurent M, Des Guetz G, Bastuji-Garin S, Culine S, Caillet P, Aparicio T, Audureau E, Carvahlo-Verlinde M, Reinald N, Tournigand C, Landre T, LeThuaut A, Paillaud E, Canouï-Poitrine F.

Am J Clin Oncol. 2018 Jan;41(1):73-80. doi: 10.1097/COC.0000000000000233.

PMID:
26669742
44.

Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients' involvement in specific therapies decision-making.

Beaussant Y, Mathieu-Nicot F, Pazart L, Tournigand C, Daneault S, Cretin E, Godard-Marceau A, Chassagne A, Trimaille H, Bouleuc C, Cuynet P, Deconinck E, Aubry R.

BMC Palliat Care. 2015 Nov 16;14:61. doi: 10.1186/s12904-015-0057-4.

45.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776
46.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.

47.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A.

Lancet Oncol. 2015 Nov;16(15):1493-1505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

PMID:
26474518
48.

Cinétique du PSA comme facteur prédictif de réponse par acétate d'abiratérone chez les patients atteints d'un cancer de la prostate en phase de résistance à la castration.

Saldana C, Chaubet-Houdu M, Joly C, Charbit D, Vordos D, Vacherot F, Salomon L, Tournigand C, De la Taille A.

Prog Urol. 2014 Nov;24(13):818-9. doi: 10.1016/j.purol.2014.08.078. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461604
49.

Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.

Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, Bastien C, de la Taille A, Boussion H, Charpy C, Jourdain A, Bléchet C, Pierron G, Gentien D, Choudat L, Tournigand C, Delattre O, Allory Y, Bourdeaut F.

Eur Urol. 2016 Jun;69(6):1055-61. doi: 10.1016/j.eururo.2015.09.027. Epub 2015 Oct 1.

PMID:
26433572
50.

State of the art and future directions of pancreatic ductal adenocarcinoma therapy.

Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P.

Pharmacol Ther. 2015 Nov;155:80-104. doi: 10.1016/j.pharmthera.2015.08.006. Epub 2015 Aug 20. Review.

PMID:
26299994

Supplemental Content

Loading ...
Support Center